Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Description:**\n3′‑Fluoro‑3′‑deoxythymidine 5′‑monophosphate is a synthetic nucleotide analogue of thymidine monophosphate in which the hydroxyl group at the ribose’s third carbon is replaced by fluorine. It belongs to the class of pyrimidone nucleotides and acts as an inhibitor or substrate for certain kinases such as Mycobacterium tuberculosis thymidylate kinase. The compound has been studied primarily as a biochemical tool and experimental agent; it was investigated in early-stage clinical trials (up to phase II) for antiviral applications but development was discontinued[1][2][4][7]. It is not approved for any therapeutic use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3'-fluoro-3'-deoxythymidine 5'-monophosphate.